(ShareCast News) - Pharmaceutical group Vectura has posted a 57% rise in interim earnings before interest, tax, depreciation and amortisation to £4.7m driven by a 35% jump in revenues to £26.1m.Vectura, which specialises in products to treat airways-related diseases, trimmed its pre-tax losses to £5m from £8m last time. This was helped by £2.4m in investment income, which includes a non-recurring receipt of £2.3m relating to the sale of its shareholding in ProFibrix.Royalties from products made with pharmaceutical partners rose 67%, while device sales were up 24%. Royalty income from the products marketed by Novartis and GSK now account for 65% of total royalty revenue against 43% last year.Royalty income also grew as a result of a sustained growth in the sales of recently launched products, Vecutra said.A favourable movement in the pound/dollar exchange added growth to revenues earned from contracts denominated in US dollars. On a constant currency basis, royalty income increased by 53%.Vectura has eight products marketed by partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies.Vectura currently has disclosed development collaborations and licence agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.Chief executive James Ward-Lilley said once the company's, Utibron, Neohaler, and Seebri Neohaler productes would provide a new royalty stream once launched in conjunction with Novartis.